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Purpose To systematically review the prognostic accuracy of fluorine-18-
fluorodeoxyglucose positron emission tomography (FDG-PET) for interim response
assessment of patients with untreated advanced-stage Hodgkin's lymphoma (HL) or
diffuse large B-cell lymphoma (DLBCL). Methods MEDLINE, EMBASE, SCOPUS, and
Biologic Abstracts were searched for relevant studies. Two assessors independently
reviewed studies for inclusion and extracted data. Relevant unpublished data were
requested from the investigators if unavailable from publications. A meta-analysis of
the prognostic accuracy was performed. Results Thirteen studies involving 360
advanced-stage HL patients and 311 DLBCL patients met our inclusion criteria.
Advanced-stage HL studies included few unfavorable-risk patients. DLBCL studies
were heterogeneous. FDG-PET had an overall sensitivity of 0.81 (95% CI, 0.72 to
0.89) and a specificity of 0.97 (95% CI, 0.94 to 0.99) for advanced-stage HL, and a
sensitivity of 0.78 (95% CI, 0.64 to 0.87) and a specificity of 0.87 (95% CI, 0.75 to
0.93) for DLBCL. Meta-regression and subgroup analyses did not identify factors that
affect prognostic accuracy. Conclusion For low- to intermediate-risk advanced-stage
HL, FDG-PET performed after a few cycles of standard chemotherapy seems to be a
reliable prognostic test to identify poor responders, warranting prospective studies to
assess PET-based treatment strategies. For DLBCL, no reliable conclusions can be
drawn due to heterogeneity. Interim PET remains an unproven test for routine clinical
practice. Its use should be reserved for research settings where treatment regimens
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